David Verbel
Overview
Explore the profile of David Verbel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
837
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meyer M, Kirmess K, Eastwood S, Wente-Roth T, Irvin F, Holubasch M, et al.
Alzheimers Dement
. 2024 Mar;
20(5):3179-3192.
PMID: 38491912
Background: With the availability of disease-modifying therapies for Alzheimer's disease (AD), it is important for clinicians to have tests to aid in AD diagnosis, especially when the presence of amyloid...
2.
Huang K, Chandra D, McGrath S, Dixit V, Zhang C, Wu J, et al.
Mol Cancer Ther
. 2023 Apr;
22(4):551.
PMID: 37009707
No abstract available.
3.
Nojima H, Ito S, Kushida A, Abe A, Motsuchi W, Verbel D, et al.
Ann Clin Transl Neurol
. 2022 Nov;
9(12):1898-1909.
PMID: 36321325
Objectives: Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) are well-established in research settings, but their use in routine clinical practice remains a largely unexploited potential. Here, we examined the...
4.
Yamashita K, Miura M, Watanabe S, Ishiki K, Arimatsu Y, Kawahira J, et al.
Alzheimers Res Ther
. 2022 Jun;
14(1):86.
PMID: 35739591
Background: Clinicians, researchers, and patients alike would greatly benefit from more accessible and inexpensive biomarkers for neural β-amyloid (Aβ). We aimed to assess the performance of fully automated plasma Aβ...
5.
Hu Y, Kirmess K, Meyer M, Rabinovici G, Gatsonis C, Siegel B, et al.
JAMA Netw Open
. 2022 Apr;
5(4):e228392.
PMID: 35446396
Importance: The diagnostic evaluation for Alzheimer disease may be improved by a blood-based diagnostic test identifying presence of brain amyloid plaque pathology. Objective: To determine the clinical performance associated with...
6.
Huang K, Chanda D, McGrath S, Dixit V, Zhang C, Wu J, et al.
Mol Cancer Ther
. 2022 Mar;
21(6):914-924.
PMID: 35313332
Stimulator of interferon genes (STING) is an innate immune receptor activated by natural or synthetic agonists to elicit antitumoral immune response via type I IFNs and other inflammatory cytokines. Bacillus...
7.
Lee L, DAngelo P, Verbel D, Martinez G, Aluri J, Brimhall D
Int J Clin Pharmacol Ther
. 2015 Jan;
53(2):190-8.
PMID: 25600977
Objective: This study assessed the impact of varying lenvatinib crystalline forms in 10-mg lenvatinib capsules on drug bioavailability in healthy volunteers. Materials: Lenvatinib 10-mg capsules (low C and high C...
8.
Dubbelman A, Rosing H, Nijenhuis C, Huitema A, Mergui-Roelvink M, Gupta A, et al.
Invest New Drugs
. 2014 Nov;
33(1):233-40.
PMID: 25377392
Lenvatinib is an orally available multi-targeted tyrosine kinase inhibitor with anti-angiogenic and antitumor activity. To get more insight into the disposition of lenvatinib, a mass balance study was performed in...
9.
Donovan M, Kotsianti A, Bayer-Zubek V, Verbel D, Teverovskiy M, Cordon-Cardo C, et al.
Eur J Cancer
. 2009 Mar;
45(8):1518-26.
PMID: 19272767
Purpose: To identify clinical and biometric features associated with overall survival of patients with advanced refractory non-small-cell lung cancer (NSCLC) treated with gefitinib. Experimental Design: One hundred and nine diagnostic...
10.
Eggener S, Vickers A, Serio A, Donovan M, Khan F, Bayer-Zubek V, et al.
Cancer
. 2008 Nov;
115(2):303-10.
PMID: 19025977
Background: Models are available to accurately predict biochemical disease recurrence (BCR) after radical prostatectomy (RP). Because not all patients experiencing BCR will progress to metastatic disease, it is appealing to...